Financial Results 9 Months 2021

Financial Results 9 Months 2021

Pillars of growth


Heavy bet for R&D
as a future
growth engine

conocer +


Heavy bet on R&D
as a future
growth engine

find out more

Biosimilar de Enoxaparina


A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.

find out more

Especialidades farmacéuticas

Pharmaceutical products

Diversified portfolio of innovative own and licensed products protected by patents.

find out more


Low Molecular Weight Heparin

ROVI's principal product, a low-molecular-weight heparin developed in-house.

find out more

Fabricación a terceros

Contract manufacturing

High production capacity with four manufacturing plants for prefilled syringes and oral solid forms.

find out more

Rovi en cifras

Rovi in figures


Net profit of the businessin 2019


2019 LMWHglobal sales

65 countries

LMWH presence through strategic alliances with international partners

6 plants

for manufacturing own and third-party products in Spain

€29,3 Mn

of investment in R&D in 2019 Commitment to innovation

7 countries

Direct presence through subsidiaries  to market Enoxaparin

Information for investors

Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.

Go to Shareholders and Investors


Last news on Rovi 

(See all items)



2021 Capital Markets Day presentation

ROVI updates its strategy in a meeting with shareholders, investors and analysts.



First Nine Months 2021 Results Press Release

Download our press release published on 3 November to find out the financial results for the first nine months of 2021.

Last annual report


Annual Report 2020

Last regular
public information


Press release